Do intellectual property (IP) rights on existing technologies hinder subsequent innovation? Using newly-collected data on the sequencing of the human genome by the public Human Genome Project and the private [...]
Congress has recently demonstrated significant ongoing interest in litigation by “patent assertion entities” (PAEs), which are colloquially known as “patent trolls” and sometimes referred to as “non-practicing entities” (NPEs). The [...]
Suits brought by [patent assertion entities, or "patent trolls"] have tripled in just the last two years, rising from 29 percent of all infringement suits to 62 percent of all [...]
This article presents an econometric analysis of the direct effects of the R&D tax credit (RTC) on private R&D investment and capital in France and proposes an ex ante evaluation [...]
A surprisingly small number of innovative firms use the patent system. In the UK, the share of firms patenting among those reporting that they have innovated is about 4%. Survey [...]
The argument in favor of a specialized court for patent appeals is that this is an area where an expert court is particularly beneficial. But that proposition is contestable from [...]
We estimate a model of drug demand and supply that incorporates insurance, advertising, and competition between branded and generic drugs within and across therapeutic classes. We use data on antiulcer [...]
Prior work suggests that more valuable patents are cited more and this view has become standard in the empirical innovation literature. Using an NPE-derived dataset with patent-specific revenues we find [...]
Pharmaceuticals and human biologic products (referred to below as "pharmaceuticals") are regulated in virtually all aspects of the product life-cycle: safety, efficacy and manufacturing quality as a condition for market [...]
We examine the impact of loss of U.S. patent exclusivity (LOE) on the prices and utilization of specialty drugs between 2001 and 2007. We limit our empirical cohort to drugs [...]